Advertisement

Multimodality Therapy

  • Jung Hoon Lee
  • Jae Hyun Jung
  • Hyeong Dong Yuk
Chapter

Abstract

Trimodality therapy (TMT) for localized muscle-invasive bladder cancer (MIBC) is a substitute for radical cystectomy. TMT consists of chemoradiation and transurethral resection of bladder tumor (TURB). The purpose of bladder preservation is to get advantage of quality of life and prevent morbidities of radical surgery with comparable oncologic outcomes. TMT could be considered not only for patients inappropriate for surgery but also for patients with MIBC who are reluctant to take surgery.

Keywords

Bladder preservation Multimodal therapy Muscle-invasive bladder cancer Trimodality therapy Transurethral resection of the bladder Chemoradiation therapy 

References

  1. 1.
    Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66:120–37.CrossRefGoogle Scholar
  2. 2.
    Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61:705–11.CrossRefGoogle Scholar
  3. 3.
    Horwich A, Dearnaley D, Huddart R, Graham J, Bessell E, Mason M, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol. 2005;75:34–43.CrossRefGoogle Scholar
  4. 4.
    Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011;29:733–8.CrossRefGoogle Scholar
  5. 5.
    Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009;27:4055–61.CrossRefGoogle Scholar
  6. 6.
    Foroudi F, Pham D, Bressel M, Wong J, Rolfo A, Roxby P, et al. Bladder cancer radiotherapy margins: a comparison of daily alignment using skin, bone or soft tissue. Clin Oncol. 2012;24:673–81.CrossRefGoogle Scholar
  7. 7.
    Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63:45–57.CrossRefGoogle Scholar
  8. 8.
    Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–73.CrossRefGoogle Scholar
  9. 9.
    Shipley WU, Prout GR Jr, Einstein AB, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258:931–5.CrossRefGoogle Scholar
  10. 10.
    Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:457–62.CrossRefGoogle Scholar
  11. 11.
    Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061–71.CrossRefGoogle Scholar
  12. 12.
    Hussain SA, Stocken DD, Peake DR, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer. 2004;90:2106–11.CrossRefGoogle Scholar
  13. 13.
    James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–88. http://dx.doi.org/10.1056/NEJMoa1106106.CrossRefGoogle Scholar
  14. 14.
    Baxter E, Dennis K, Kollmannsberger C, Black P, Attwell A, Morris WJ, et al. Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience. Urol Oncol. 2015;33:66.e13–9.CrossRefGoogle Scholar
  15. 15.
    Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kubler H, et al. A systemic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36:43–53.CrossRefGoogle Scholar
  16. 16.
    Zapatero A, Martin De Vidales C, Arellano R, et al. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology. 2012;80:1056–62.CrossRefGoogle Scholar
  17. 17.
    Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debre´ B, Zerbib M. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology. 2004;63:73–7.CrossRefGoogle Scholar
  18. 18.
    Tilki D, Shariat SF, Lotan Y, et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013;111:1215–21.CrossRefGoogle Scholar
  19. 19.
    Watts KL, Ristau BT, Yamase HT, Taylor JA 3rd. Prognostic implications of lymph node involvement in bladder cancer: are we understaging using current methods? BJU Int. 2011;108:484–92.CrossRefGoogle Scholar
  20. 20.
    Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol. 2017;71(6):952–60. http://dx.doi.org/10.1016/j.eururo.2016.12.020.
  21. 21.
    Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, et al. RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:665–72.CrossRefGoogle Scholar
  22. 22.
    Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys. 2007;68:1072–80.CrossRefGoogle Scholar
  23. 23.
    Onozawa M, Miyanaga N, Hinotsu S, Miyazaki J, Oikawa T, Kimura T, et al. Analysis of intravesical recurrence after bladder-preserving therapy for muscle-invasive bladder cancer. Jpn J Clin Oncol. 2012;42(9):825–30.CrossRefGoogle Scholar
  24. 24.
    Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol. 2006;81:9–17.CrossRefGoogle Scholar
  25. 25.
    Aboziada MA, Hamza HM, Abdlrahem AM. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma. J Egypt Natl Canc Inst. 2009;21:167–74.PubMedGoogle Scholar
  26. 26.
    Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012;187:463–8.CrossRefGoogle Scholar
  27. 27.
    Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N, et al. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 2011;41:1373–9.CrossRefGoogle Scholar
  28. 28.
    Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.  https://doi.org/10.1200/jco.2001.19.3.666.CrossRefPubMedGoogle Scholar
  29. 29.
    Dalbagni G, Genega E, Hashibe MIA, Zhang Z-F, Russo P, Herr H, et al. Cystectomy for bladder cancer: A contemporary series. J Urol. 2001;165(4):1111–6.CrossRefGoogle Scholar
  30. 30.
    Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. https://doi.org/10.1056/NEJMoa022148.CrossRefPubMedGoogle Scholar
  31. 31.
    Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–9. https://doi.org/10.1200/jco.2014.57.5548.CrossRefGoogle Scholar
  32. 32.
    Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006;176:486–92.CrossRefGoogle Scholar
  33. 33.
    Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690–6.CrossRefGoogle Scholar
  34. 34.
    Azuma H, Yamamoto K, Inamoto T, Ibuki N, Kotake Y, Sakamoto T, et al. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Am J Clin Oncol. 2009;32:592–606.CrossRefGoogle Scholar
  35. 35.
    AlGizawy SM, Essa HH, Abdel-Wanis ME, Abdel Raheem AM. Trimodality bladdersparing approach versus radical cystectomy for invasive bladder cancer. J Radiother Pract. 2014;13:428–37.CrossRefGoogle Scholar
  36. 36.
    Zietman AL, Sacco D, Skowronski URI, Gomery P, Kaufman DS, Clark JA, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170:1772–6.CrossRefGoogle Scholar
  37. 37.
    Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng J-S, et al. Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2016;96:1028–36.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Jung Hoon Lee
    • 1
  • Jae Hyun Jung
    • 1
  • Hyeong Dong Yuk
    • 1
  1. 1.Seoul National University HospitalSeoulSouth Korea

Personalised recommendations